MPWT
MRNS

MassMutual Private Wealth & Trust’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-97
Closed – – 1860
2022
Q2 		$0 Buy
+97
New +$590 ﹤0.01% 1762

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

MassMutual Private Wealth & Trust's MRNS Position: Q3 2022 in Review

MassMutual Private Wealth & Trust sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2022, closing a stake of 97 shares.

MassMutual Private Wealth & Trust first reported a position in MRNS in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 69 funds tracked by Wall St. Rank hold MRNS as of Q3 2022.

  • MassMutual Private Wealth & Trust reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2022 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 97 Marinus Pharmaceuticals, Inc shares in Q3 2022.
  • MassMutual Private Wealth & Trust first reported a position in Marinus Pharmaceuticals, Inc in Q2 2022 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's Marinus Pharmaceuticals, Inc position peaked at $0 in Q2 2022.
  • 69 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2022.

Based on MassMutual Private Wealth & Trust's 13F filing for Q3 2022, filed 7 Oct 2022.